SCHEMBL1764094

SCHEMBL1764094

COc1ccc(C(O)(c2ccc(OC)cc2)c2ccc(C(=O)ON3C(=O)CCC3=O)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
KMT2A Q03164 3/20 0.44
MAPT P10636 2/20 0.44
RECQL P46063 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
THRB P10828 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
BLM P54132 1/20 0.44
POLB P06746 3/20 0.42
ATM Q13315 1/20 0.41
ALDH1A1 P00352 3/20 0.40
LMNA P02545 1/20 0.40
ALOX15 P16050 1/20 0.40
APEX1 P27695 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14023026 1.00 CA1 (0.45) CA1CA2KMT2AMAPTRECQL
SCHEMBL8824305 0.95 POLB (0.44) CA1CA2KMT2AMAPTRECQL
SCHEMBL12594345 0.95 KMT2A (0.44) CA1CA2KMT2AMAPTRECQL
SCHEMBL7740161 0.90 CA1 (0.55) CA1CA2KMT2AMAPTRECQL
SCHEMBL14023036 0.88 CA1 (0.44) CA1CA2KMT2AMAPTRECQL
SCHEMBL766395 0.88 CA1 (0.44) CA1CA2KMT2AMAPTRECQL
SCHEMBL8824309 0.88 KMT2A (0.43) KMT2AMAPTRECQLKDM4EMEN1
SCHEMBL14022988 0.85 POLB (0.44) CA1CA2KMT2AMAPTRECQL
SCHEMBL8824297 0.85 CYP19A1 (0.41) CA1KMT2AMAPTMEN1LMNA
SCHEMBL3612061 0.84 POLB (0.43) CA1CA2KMT2AMAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5410068-A Protecting groups for natural products PERSEPTIVE BIOSYSTEMS, INC. (US) 1995-04-25 US claimed
US-9034798-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2015-05-19 US disclosed
US-9034798-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2015-05-19 US disclosed
US-8569481-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PHARMACEUTICALS, INC. (US) 2013-10-29 US disclosed
US-8569481-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PHARMACEUTICALS, INC. (US) 2013-10-29 US disclosed
US-8268264-B2 Devices, systems and methods for separating magnetic particles CAPROTEC BIOANALYTICS GMBH (DE) 2012-09-18 US disclosed
US-8268264-B2 Devices, systems and methods for separating magnetic particles CAPROTEC BIOANALYTICS GMBH (DE) 2012-09-18 US disclosed
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions KOESTER HUBERT 2011-05-19 US disclosed
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions KOESTER HUBERT 2011-05-19 US disclosed
US-7858560-B2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2010-12-28 US disclosed
US-20100248264-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-09-30 US disclosed
US-20100248264-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions HK PHARMACEUTICALS, INC. 2010-09-30 US disclosed
US-20100200405-A1 Devices, systems and methods for separating magnetic particles CAPROTEC BIOANALYTICS GMBH (DE) 2010-08-12 US disclosed
US-20100200405-A1 Devices, systems and methods for separating magnetic particles CAPROTEC BIOANALYTICS GMBH (DE) 2010-08-12 US disclosed
WO-2010089138-A1 DEVICES, SYSTEMS AND METHODS FOR SEPARATING MAGNETIC PARTICLES CAPROTEC BIOANALYTICS GMBH (DE) 2010-08-12 WO disclosed
EP-2053406-A2 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions caprotec bioanalytics GmbH (DE) 2009-04-29 EP disclosed
US-5612474-A ANTIBODIES AND IMMUNOLOGY ELI LILLY AND COMPANY (US) 1997-03-18 US disclosed
US-5410068-A Protecting groups for natural products PERSEPTIVE BIOSYSTEMS, INC. (US) 1995-04-25 US disclosed
EP-0424819-B1 Reversible modification of biological compounds for detection, separation and purification thereof MILLIPORE CORP (US) 1994-12-28 EP disclosed
EP-0424819-A1 Reversible modification of biological compounds for detection, separation and purification thereof MILLIPORE CORPORATION (US) 1991-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118136-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions PTMS, QPCTL, SRMS CA1 1844/4885CA2 2516/4885KMT2A 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.